Guggenheim analyst Subbu Nambi raised the firm’s price target on Castle Biosciences (CSTL) to $47 from $43 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Reports Strong Preliminary 2025 Revenue Growth
- Castle Biosciences: Broad-Based Test Growth, Strengthening Cash Generation, and Pipeline Upside Support Reiterated Buy and $50 Target
- Castle Biosciences price target raised to $52 from $35 at Lake Street
- Castle Biosciences expects FY25 revenue to exceed $340M
- Castle Biosciences price target raised to $43 from $30 at Guggenheim